Research and Markets: PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hc32mx/pharmapoint) has announced the addition of the "PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update" report to their offering.
“PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update”
Future Flu Vaccines Aimed at Children and the Elderly
In a mature market with fierce competition, firms operating in the seasonal influenza vaccine industry are increasingly focused on developing products for the high-risk, but underserved, patient pools of the elderly and children under two years of age, finds healthcare industry experts The authors in a new report.
The report says that the main drivers of the global market over the next decade will be an increased focus on the production of treatments for these vulnerable populations by introducing quadrivalent vaccines and vaccines with a better route of administration.
In a bid to tap into this burgeoning sector, pharmaceutical giant Sanofi recently released Fluzone High-Dose - a vaccine specifically designed to have improved efficacy in elderly patients. Fluad, an adjuvanted vaccine from Swiss multinational firm Novartis, is currently undergoing FDA review for approval in the US market. AstraZeneca's intranasal influenza vaccine, FluMist, enters the EU market in 2012.
According to The authors, flu vaccines currently on the market have satisfactory efficacy for most individuals, but achieving adequate vaccination coverage in most countries remains a problem. With varying levels of healthcare and reimbursement infrastructure, patients in emerging markets are at a distinct disadvantage compared to patients from Western countries, such as the US and Europe.
The authors's report also states that despite a crowded field of competitors, there still remains the opportunity for new vaccines with novel routes of administration, innovative methods of production (i.e., cell culture- or recombinant-based), or enhanced efficacy in elderly patients to take a slice of a multi-billion dollar global market.
From a 2012 estimated valuation of US$2.4 billion, the global seasonal influenza vaccines market is predicted to reach US$3 billion by 2022.
By 2022, the US is expected to generate the largest revenue with 47% of the total market, while Japan is predicted to be second with a 14% share. The top 5 EU markets are forecast to hold 16%, while the combined markets of India and China will make up the remaining 13%.In 2011, the share of gas in the US power mix was a little over 41%, but while natural gas energy production will continue to grow, its share in the national power mix is expected to fall by 1.6% by 2020, thanks in no small part to government initiated renewable energy initiatives.
Key Topics Covered
- Disease Overview
- Disease Management
- Competitive Assessment
- Opportunity and Unmet Need
- Pipeline Assessment
- Current and Future Players
- Market Outlook
- AstraZeneca (MedImmune)
- CSL Biotherapies
- Protein Sciences Corporation
For more information visit http://www.researchandmarkets.com/research/hc32mx/pharmapoint
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.